News & Resources

Macromoltek Launches Tools For Antibody Modeling Workspace

April 10, 2017

                Macromoltek (www.macromoltek.com), an early stage biotech software company located in Austin, Texas, has launched their new molecular modeling workspace to aid in the analysis and design of therapeutic antibodies. After the Phase I and Phase II Small Business Innovation Research (SBIR) grant by the National Science Foundation (NSF), the Macromoltek team has developed a molecular modeling suite focused on helping biotech companies get antibody therapeutics to market more quickly. Therapeutic antibodies can be engineered to specifically target pathogens, cancer cells, and toxins, making them powerful treatment options for patients. In addition to their therapeutic power, the attractiveness of these drugs is driven in part by their higher rate of FDA approval compared to small molecule therapies. However, the development of therapeutic antibodies remains a highly expensive and risky process that is fraught with obstacles. The goal of Macromoltek is to provide digital tools that allow for the development of more effective and safer therapeutic antibodies. The new molecular modeling package allows for analysis and design of antibodies with a simple web interface. In collaboration with researchers at the University of Texas at Austin, Macromoltek has demonstrated that antibodies that were humanized using the new online workspace demonstrated similar function to murine antibodies that had been produced using traditional methods. By digitally modeling antibodies, researchers visualize their antibody in 3-D which allows them to identify problem areas and improve function. This powerful digital tool allows for early identification of problems that might arise during later stages of development, allowing for a more effective use of resources on molecules with a higher likelihood of success.

About Macromoltek
Macromoltek helps biotech and pharmaceutical companies reduce the cost and time to market of new drugs by moving experiments to the cloud. We are focused on reducing the time, money and effort spent learning and using computational tools for drug development, especially in the area of protein molecular modeling. We offer an online workspace for antibody analysis and antibody modeling where users can store their data securely and access it at any time, from anywhere. Through our workspaces, users access state-of-the-art tools to manipulate their data and increase their understanding of the structures, leading to faster and cheaper biologics drugs. www.macromoltek.com